These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34844712)

  • 21. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer.
    Isaacsson Velho P; Silberstein JL; Markowski MC; Luo J; Lotan TL; Isaacs WB; Antonarakis ES
    Prostate; 2018 Apr; 78(5):401-407. PubMed ID: 29368341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Implications of Germline Testing in Newly Diagnosed Prostate Cancer.
    Loeb S; Giri VN
    Eur Urol Oncol; 2021 Feb; 4(1):1-9. PubMed ID: 33390340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating Germline Testing Panels in Southern African Males With Advanced Prostate Cancer.
    Gheybi K; Jiang J; Mutambirwa SBA; Soh PXY; Kote-Jarai Z; Jaratlerdsiri W; Eeles RA; Bornman MSR; Hayes VM
    J Natl Compr Canc Netw; 2023 Mar; 21(3):289-296.e3. PubMed ID: 36898365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Germline genetics of prostate cancer.
    Khan HM; Cheng HH
    Prostate; 2022 Aug; 82 Suppl 1(Suppl 1):S3-S12. PubMed ID: 35657157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.
    Mitra AV; Bancroft EK; Barbachano Y; Page EC; Foster CS; Jameson C; Mitchell G; Lindeman GJ; Stapleton A; Suthers G; Evans DG; Cruger D; Blanco I; Mercer C; Kirk J; Maehle L; Hodgson S; Walker L; Izatt L; Douglas F; Tucker K; Dorkins H; Clowes V; Male A; Donaldson A; Brewer C; Doherty R; Bulman B; Osther PJ; Salinas M; Eccles D; Axcrona K; Jobson I; Newcombe B; Cybulski C; Rubinstein WS; Buys S; Townshend S; Friedman E; Domchek S; Ramon Y Cajal T; Spigelman A; Teo SH; Nicolai N; Aaronson N; Ardern-Jones A; Bangma C; Dearnaley D; Eyfjord J; Falconer A; Grönberg H; Hamdy F; Johannsson O; Khoo V; Kote-Jarai Z; Lilja H; Lubinski J; Melia J; Moynihan C; Peock S; Rennert G; Schröder F; Sibley P; Suri M; Wilson P; Bignon YJ; Strom S; Tischkowitz M; Liljegren A; Ilencikova D; Abele A; Kyriacou K; van Asperen C; Kiemeney L; ; Easton DF; Eeles RA
    BJU Int; 2011 Jan; 107(1):28-39. PubMed ID: 20840664
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combined Effect of a Polygenic Risk Score and Rare Genetic Variants on Prostate Cancer Risk.
    Darst BF; Sheng X; Eeles RA; Kote-Jarai Z; Conti DV; Haiman CA
    Eur Urol; 2021 Aug; 80(2):134-138. PubMed ID: 33941403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of Inherited Mutations in DNA Repair Genes with Localized Prostate Cancer.
    Lee DJ; Hausler R; Le AN; Kelly G; Powers J; Ding J; Feld E; Desai H; Morrison C; Doucette A; Gabriel P; Genetics Center R; Judy RL; Weaver J; Kember R; Damrauer SM; Rader DJ; Domchek SM; Narayan V; Schwartz LE; Maxwell KN
    Eur Urol; 2022 Jun; 81(6):559-567. PubMed ID: 34711450
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polygenic Risk Scores in Prostate Cancer Risk Assessment and Screening.
    Byrne L; Toland AE
    Urol Clin North Am; 2021 Aug; 48(3):387-399. PubMed ID: 34210493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel.
    Leongamornlert DA; Saunders EJ; Wakerell S; Whitmore I; Dadaev T; Cieza-Borrella C; Benafif S; Brook MN; Donovan JL; Hamdy FC; Neal DE; Muir K; Govindasami K; Conti DV; Kote-Jarai Z; Eeles RA
    Eur Urol; 2019 Sep; 76(3):329-337. PubMed ID: 30777372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene and pathway level analyses of germline DNA-repair gene variants and prostate cancer susceptibility using the iCOGS-genotyping array.
    Saunders EJ; Dadaev T; Leongamornlert DA; Al Olama AA; Benlloch S; Giles GG; Wiklund F; Gronberg H; Haiman CA; Schleutker J; Nordestgaard BG; Travis RC; Neal D; Pasayan N; Khaw KT; Stanford JL; Blot WJ; Thibodeau SN; Maier C; Kibel AS; Cybulski C; Cannon-Albright L; Brenner H; Park JY; Kaneva R; Batra J; Teixeira MR; Pandha H; Govindasami K; Muir K; ; ; ; Easton DF; Eeles RA; Kote-Jarai Z
    Br J Cancer; 2016 Apr; 114(8):945-52. PubMed ID: 26964030
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Men with a susceptibility to prostate cancer and the role of genetic based screening.
    Eeles R; Ni Raghallaigh H
    Transl Androl Urol; 2018 Feb; 7(1):61-69. PubMed ID: 29594021
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
    Giri VN; Hegarty SE; Hyatt C; O'Leary E; Garcia J; Knudsen KE; Kelly WK; Gomella LG
    Prostate; 2019 Mar; 79(4):333-339. PubMed ID: 30450585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Germline pathogenic variants in unselected Korean men with prostate cancer.
    So MK; Ahn HK; Huh J; Kim KH
    Investig Clin Urol; 2022 May; 63(3):294-300. PubMed ID: 35534218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Considerations of germline testing in prostate cancer screening.
    Polascik TJ; Orabi H
    Can J Urol; 2019 Oct; 26(5 Suppl 2):46-47. PubMed ID: 31629431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Common Germline Risk Variants Impact Somatic Alterations and Clinical Features across Cancers.
    Namba S; Saito Y; Kogure Y; Masuda T; Bondy ML; Gharahkhani P; Gockel I; Heider D; Hillmer A; Jankowski J; MacGregor S; Maj C; Melin B; Ostrom QT; Palles C; Schumacher J; Tomlinson I; Whiteman DC; Okada Y; Kataoka K
    Cancer Res; 2023 Jan; 83(1):20-27. PubMed ID: 36286845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of a Multiethnic Polygenic Risk Score Model for Prostate Cancer.
    Plym A; Penney KL; Kalia S; Kraft P; Conti DV; Haiman C; Mucci LA; Kibel AS
    J Natl Cancer Inst; 2022 May; 114(5):771-774. PubMed ID: 33792693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Germline genetic variants in men with prostate cancer and one or more additional cancers.
    Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
    Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prostate cancer: germline prediction for a commonly variable malignancy.
    Bambury RM; Gallagher DJ
    BJU Int; 2012 Dec; 110(11 Pt C):E809-18. PubMed ID: 22974436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of BRCA1 and BRCA2 in prostate cancer.
    Castro E; Eeles R
    Asian J Androl; 2012 May; 14(3):409-14. PubMed ID: 22522501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetically Informed Prostate Cancer Treatment for Metastatic Disease.
    Siebert AL; Szymaniak BM; Numan Y; Morgans AK
    Urol Clin North Am; 2021 Aug; 48(3):365-371. PubMed ID: 34210491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.